Skip Nav Destination
Issues
1 January 2007
-
Cover Image
Cover Image
X-ray crystal structures of flavonoids bound to the ATP-binding site of the PIM1 kinase. Two distinct orientations were observed. Quercetagetin orients the B ring inside the pocket (orientation I), whereas both myricetin and 5,7,3′,4′,5′-pentahydroxyflavone flip the B ring out toward solvent (orientation II). Both binding orientations have been observed in the crystal structures of flavonoids bound to other kinases. Quercetin in complex with phosphatidylinositol 3-kinase γ (1E8W) and fisetin in complex with cyclin-dependent kinase 6 (1XO2) represent orientation I, whereas quercetin in complex with hematopoetic cell kinase (2HCK) exemplifies orientation II. For details, see Holder et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Drug Development Series: Review
Reviews
Research Articles: Therapeutics, Targets, and Development
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Deborah L. Marrocco; Wayne D. Tilley; Tina Bianco-Miotto; Andreas Evdokiou; Howard I. Scher; Richard A. Rifkind; Paul A. Marks; Victoria M. Richon; Lisa M. Butler
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint
Shi-Ken Sha; Takuji Sato; Hidetaka Kobayashi; Machiyo Ishigaki; Sayaka Yamamoto; Hitoshi Sato; Asako Takada; Sigetosi Nakajyo; Yasuo Mochizuki; Jonathan M. Friedman; Fong-Chi Cheng; Takashi Okura; Ryohei Kimura; Donald W. Kufe; Daniel D. VonHoff; Takumi Kawabe
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes
Melinda S. Yates; Masafumi Tauchi; Fumiki Katsuoka; Kathleen C. Flanders; Karen T. Liby; Tadashi Honda; Gordon W. Gribble; Delinda A. Johnson; Jeffrey A. Johnson; Neal C. Burton; Tomás R. Guilarte; Masayuki Yamamoto; Michael B. Sporn; Thomas W. Kensler
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia–mutated nuclear protein kinase activation
Shin-Hun Juang; Chia-Chi Lung; Pi-Chen Hsu; Kuo-Shun Hsu; Yu-Chen Li; Pao-Chiung Hong; Her-Shyong Shiah; Ching-Chuan Kuo; Ching-Wei Huang; Yu-Chin Wang; Leeyuan Huang; Tom S. Chen; Shyh-Fong Chen; Kuo-Chu Fu; Cheng-Li Hsu; Meng-Ju Lin; Ching-jer Chang; Curtis L. Ashendel; Thomas C.K. Chan; Kai-Ming Chou; Jang-Yang Chang
A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas
Farzan Siddiqui; Chuan-Yuan Li; Susan M. LaRue; Jean M. Poulson; Paul R. Avery; Amy F. Pruitt; Xiuwu Zhang; Robert L. Ullrich; Donald E. Thrall; Mark W. Dewhirst; Marlene L. Hauck
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.